Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial

BMC Dermatology ◽

10.1186/s12895-016-0051-4 ◽

2016 ◽

Vol 16 (1) ◽

Author(s):

Kim A. Papp ◽

Robert Bissonnette ◽

Melinda Gooderham ◽

Steven R. Feldman ◽

Lars Iversen ◽

...

Keyword(s):

Clinical Trial ◽

Randomized Clinical Trial ◽

Plaque Psoriasis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Janus Kinase Inhibitor ◽

Ointment Formulation

Download Full-text

Efficacy and safety of topical janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis: Results of a phase IIA randomized clinical trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2012.12.823 ◽

2013 ◽

Vol 68 (4) ◽

pp. AB199

Keyword(s):

Clinical Trial ◽

Randomized Clinical Trial ◽

Plaque Psoriasis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Janus Kinase Inhibitor

Download Full-text

An evaluation of the effect of tasocitinib (CP-690,550), an oral Janus kinase inhibitor, on pruritus in patients with plaque psoriasis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2010.09.597 ◽

2011 ◽

Vol 64 (2) ◽

pp. AB146

Keyword(s):

Plaque Psoriasis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Janus Kinase Inhibitor

Download Full-text

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2016.01.013 ◽

2016 ◽

Vol 74 (5) ◽

pp. 841-850 ◽

Author(s):

Kim A. Papp ◽

James G. Krueger ◽

Steven R. Feldman ◽

Richard G. Langley ◽

Diamant Thaci ◽

...

Keyword(s):

Plaque Psoriasis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Phase Iii ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Janus Kinase Inhibitor ◽

Phase Iii Studies

Download Full-text

OP0046 Tofacitinib, an Oral Janus Kinase Inhibitor, in a Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy in a Phase 3 Randomised Clinical Trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.251 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A65.1-A65

Author(s):

M. Genovese ◽

R. van Vollenhoven ◽

B. Wilkinson ◽

L. Wang ◽

S. Zwillich ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Trial ◽

Kinase Inhibitor ◽

Randomised Clinical Trial ◽

Janus Kinase ◽

Phase 3 ◽

Janus Kinase Inhibitor ◽

Adalimumab Therapy ◽

Open Label Extension

Download Full-text

Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight

CPT Pharmacometrics & Systems Pharmacology ◽

10.1002/psp4.12182 ◽

2017 ◽

Vol 6 (5) ◽

pp. 322-330 ◽

Author(s):

MM Hutmacher ◽

K Papp ◽

S Krishnaswami ◽

K Ito ◽

H Tan ◽

...

Keyword(s):

Body Weight ◽

Plaque Psoriasis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Janus Kinase Inhibitor

Download Full-text

Efficacy of topical tofacitinib, a Janus kinase inhibitor, in the treatment of plaque psoriasis

Dermatologic Therapy ◽

10.1111/dth.12467 ◽

2017 ◽

Vol 30 (3) ◽

pp. e12467 ◽

Author(s):

Nooshin Bagherani ◽

Bruce R. Smoller

Keyword(s):

Plaque Psoriasis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Janus Kinase Inhibitor

Download Full-text

The itch severity item: Mediation modeling and measurement characteristics from a phase IIb trial of tasocitinib (CP-690,550), an oral Janus kinase inhibitor, in patients with plaque psoriasis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2010.09.623 ◽

2011 ◽

Vol 64 (2) ◽

pp. AB152

Keyword(s):

Plaque Psoriasis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Janus Kinase Inhibitor ◽

Mediation Modeling

Download Full-text

THU0187 Safety of Tofacitinib, An Oral Janus Kinase Inhibitor: Integrated Data Analysis from The Global Chronic Plaque Psoriasis Clinical Trials

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2016-eular.2394 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 253.1-253

Author(s):

R.G.B. Langley ◽

A.D. Cohen ◽

P. Foley ◽

C.E.M. Griffiths ◽

M. Lebwohl ◽

...

Keyword(s):

Clinical Trials ◽

Data Analysis ◽

Plaque Psoriasis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Chronic Plaque Psoriasis ◽

Janus Kinase Inhibitor ◽

Integrated Data Analysis

Download Full-text

LB780 Randomized, blind, placebo-controlled clinical trial on the clinical efficacy of oclacitinib, an oral janus kinase inhibitor, in a canine model of spontaneously occurring atopic dermatitis

Journal of Investigative Dermatology ◽

10.1016/j.jid.2016.05.030 ◽

2016 ◽

Vol 136 (8) ◽

pp. B6

Author(s):

R. Marsella

Keyword(s):

Clinical Trial ◽

Atopic Dermatitis ◽

Clinical Efficacy ◽

Kinase Inhibitor ◽

Canine Model ◽

Janus Kinase ◽

Controlled Clinical Trial ◽

Janus Kinase Inhibitor

Download Full-text

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis

CPT Pharmacometrics & Systems Pharmacology ◽

10.1038/psp.2013.22 ◽

2013 ◽

Vol 2 (5) ◽

pp. 44 ◽

Author(s):

H Tan ◽

P Gupta ◽

J Harness ◽

R Wolk ◽

S Chapel ◽

...

Keyword(s):

Dose Response ◽

Plaque Psoriasis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Chronic Plaque Psoriasis ◽

Janus Kinase Inhibitor

Download Full-text